A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.

NCT01440361 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped This study was Cancelled Before Active

Conditions

Purpura, Thrombocytopaenic, Idiopathic

Interventions

DRUG: Belimumab
DRUG: Normal saline placebo

Sponsor

GlaxoSmithKline